Related Experiment Video
Updated: Jul 4, 2026
06:58
Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
TDP-43 in neurodegenerative disorders
Casey Cook1, Yong-jie Zhang, Ya-fei Xu
1Mayo Clinic, 4500 San Pablo Road Jacksonville, Florida 32224, USA.
Expert Opinion on Biological Therapy
|June 14, 2008
Summary
TDP-43 proteinopathies, linked to neurodegenerative diseases, involve abnormal transactivation response element (TAR)-DNA-binding protein 43 (TDP-43) aggregation. Research is exploring therapeutic strategies and the connection between mutations and TDP-43 pathology.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Increasing recognition of neurodegenerative diseases linked to transactivation response element (TAR)-DNA-binding protein 43 (TDP-43) aggregates, termed TDP-43 proteinopathies.
- Biochemical hallmarks include reduced TDP-43 solubility, hyperphosphorylation, cleavage into 25/35-kDa fragments, and altered cellular localization.
Purpose of the Study:
- To review the distribution of TDP-43 pathology in human postmortem brain tissue.
- To discuss potential therapeutic strategies informed by genetic and in vitro research.
Main Methods:
- Comprehensive review of recent scientific literature on TDP-43 proteinopathy.
- Analysis of studies investigating TDP-43 pathology distribution and therapeutic targets.
Main Results:
- Characterization of TDP-43 pathology distribution in human brain tissue (details not specified in abstract).
- Identification of potential therapeutic avenues based on genetic and in vitro findings (details not specified in abstract).
Conclusions:
- Multiple mutations, including those in progranulin and valosin-containing protein, can precipitate TDP-43 proteinopathies.
- Further research is essential to elucidate and potentially leverage the relationship between these genetic mutations and TDP-43 pathology.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...